Medicenna reports promising survival gains from the Phase 2b trial of Bizaxofusp for relapsed Glioblastoma, revealed at the 28th yearly NeuroOncology Society gathering.

On 14 Apr 2023, data from first-in-human study of EXS21546, an A2A receptor antagonist, was reported at the AACR Congress.

EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.

The development of inhibitors around the entire CDK family has become an important branch of drug development in the field of oncology in recent years.

US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.

The initial results from LOXO-RAS-20001, a phase 1 study of LY3537982 in patients (pts) with KRAS G12C-mutant advanced solid tumors were reported at the AACR Congress.

Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.

Inhibiting the downstream ERK can block cell signal transduction, and ERK inhibitors can overcome tumor cells' resistance to upstream target inhibitors. This gives them broader application prospects in clinical settings.

Astellas and Pfizer's XTANDI® gets FDA approval for update, following fast-tracked review and EMBARK study results.

On 11 Dec 2023, the updated clinical results of Axatilimab at 3 different doses in patients with Chronic Graft-Versus-Host Disease (AGAVE-201) will be reported in 2023 ASH.

Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.

The application of DPP-4 inhibitors brings new hope to the treatment of Type 2 Diabetes.